Department of Trauma Surgery, Gachon University Gil Medical Center, Incheon, Republic of Korea.
Department of Traumatology, Gachon University College of Medicine, Incheon, Republic of Korea.
Int J Artif Organs. 2022 Oct;45(10):833-840. doi: 10.1177/03913988221116649. Epub 2022 Aug 2.
The use of extracorporeal membrane oxygenation (ECMO) has increased, although its survival benefit in trauma patients with severe adult respiratory distress syndrome (ARDS) remains controversial. We investigated the effect of veno-venous (VV)-ECMO on the clinical outcomes of trauma patients with severe ARDS.
This was a retrospective study at a single center comprising trauma patients admitted between January 2013 and December 2017, diagnosed with severe ARDS using the Berlin definition (PaO2/FiO2 ratio ⩽100), in the 7 days following trauma. Patients were managed with VV-ECMO or conventional mechanical ventilation (CMV). The primary outcome was in-hospital mortality (mortality at 60 days); secondary outcomes comprised 28-day mortality, hospital length of stay (LOS), intensive care unit (ICU) LOS, ICU-free days, duration of mechanical ventilation (MV), and MV-free days. Propensity score matching was performed to adjust for the baseline differences.
Sixteen patients (22.5%) were managed with VV-ECMO and 55 were managed with CMV. After matching, the in-hospital mortality rate (43.8% vs 53.1%; = 0.760), 28-day mortality rate (37.5% vs 31.3%; = 0.750), median hospital LOS (39.5 vs 36.5 days; = 0.533), ICU-free days (0 vs 0 days; = 0.241), and MV-free days (0 vs 0 days; = 0.272) did not significantly differ between the VV-ECMO and CMV groups.
In-hospital mortality (mortality at 60 days) did not differ significantly between the VV-ECMO and CMV groups. Although the safety of ECMO in trauma patients requires further investigation, VV-ECMO may be considered as a rescue therapy.
体外膜肺氧合(ECMO)的使用有所增加,尽管其在创伤后合并严重成人呼吸窘迫综合征(ARDS)患者中的生存获益仍存在争议。我们研究了静脉-静脉(VV)-ECMO 对创伤后合并严重 ARDS 患者临床结局的影响。
这是一项单中心回顾性研究,纳入 2013 年 1 月至 2017 年 12 月期间创伤后 7 天内诊断为严重 ARDS(柏林定义:氧合指数 PaO2/FiO2 比值 ⩽100)的患者。患者接受 VV-ECMO 或常规机械通气(CMV)治疗。主要结局为住院死亡率(60 天死亡率);次要结局包括 28 天死亡率、住院时间(LOS)、重症监护病房(ICU)LOS、ICU 无机械通气天数、机械通气时间(MV)、MV 无机械通气天数。采用倾向评分匹配法调整基线差异。
16 例(22.5%)患者接受 VV-ECMO 治疗,55 例患者接受 CMV 治疗。匹配后,VV-ECMO 组和 CMV 组的住院死亡率(43.8% vs 53.1%; = 0.760)、28 天死亡率(37.5% vs 31.3%; = 0.750)、中位住院 LOS(39.5 天 vs 36.5 天; = 0.533)、ICU 无机械通气天数(0 天 vs 0 天; = 0.241)和 MV 无机械通气天数(0 天 vs 0 天; = 0.272)无显著差异。
VV-ECMO 组和 CMV 组的住院死亡率(60 天死亡率)无显著差异。尽管 ECMO 在创伤患者中的安全性仍需进一步研究,但 VV-ECMO 可作为一种挽救性治疗。